From: Efficacy and safety of i.v. sodium benzoate in urea cycle disorders: a multicentre retrospective study
Causes
Patients
N = 61 (%)
Episodes
N = 95 (%)
OTCD
20 (32.8 %)
35 (36.8 %)
ASSD
18 (29.5 %)
30 (31.6 %)
CPSD
15 (24.6 %)
18 (18.9 %)
ASLD
3 (4.9 %)
4 (4.2 %)
ARGD
1 (1.6 %)
2 (2.1 %)
NAGSD
Others
3 (4.9 %)*